Best Appetite Suppressant 2026: FDA-Approved Pills, Injections & Drugs Compared

“Best appetite suppressant” in 2026 has more meanings than the search query suggests. The FDA-approved landscape includes injectable GLP-1s (Wegovy, Zepbound, Saxenda) producing the largest weight-loss numbers, oral GLP-1 (Foundayo, FDA-approved April 2026) for patients who prefer pills, older non-GLP-1 prescription pills (Qsymia, Contrave, Xenical/alli) with smaller effect sizes but established multi-decade safety records, and the original Schedule IV controlled appetite suppressant (Phentermine, FDA-approved 1959). The “best” depends on which trade-offs match your situation. Below: all 8 FDA-approved options side-by-side with verbatim DailyMed data and primary-source phase 3 trial efficacy.

All 8 FDA-approved appetite suppressants side-by-side

Note: this list covers FDA-approved chronic weight management drugs. The major GLP-1s that are FDA-approved for type 2 diabetes only — Trulicity (dulaglutide), Ozempic (semaglutide), Mounjaro (tirzepatide), Rybelsus (oral semaglutide), Victoza (liraglutide), Byetta/Bydureon (exenatide) — are not on this comparison because they are not labeled for weight management. Trulicity in particular is worth a separate look as the “older sibling” once-weekly GLP-1: it produces real but smaller weight loss off-label (-4.6 kg at 4.5 mg max dose at 36 weeks per AWARD-11) and has the deepest cardiovascular outcomes evidence base (REWIND, 12% MACE reduction). See our Trulicity (dulaglutide) for weight loss evidence guide and the T2D vs weight-management GLP-1 disambiguation .

Ranked by published weight-loss efficacy

From largest to smallest documented mean weight loss in their canonical phase 3 trials:

1. Zepbound (tirzepatide): ~20.9% at 72 wk on 15 mg (SURMOUNT-1)
2. Wegovy (semaglutide): ~14.9% at 68 wk on 2.4 mg (STEP-1)
3. Foundayo (orforglipron): ~12-15% range at maximum labeled dose (label data; long-term comparisons pending)
4. Qsymia (phentermine + topiramate ER): -9.8% at 56 wk on 15/92 mg (CONQUER)
5. Saxenda (liraglutide 3 mg): -5 to -8% at 56 wk (SCALE)
6. Contrave (naltrexone + bupropion): -5.0 to -6.4% at 56 wk (COR-I, COR-II)
7. Xenical (orlistat 120 mg): -5.17% at 4 years (XENDOS)
8. Phentermine (monoproduct): short-term, smaller effect; no modern phase 3 framework

Honest caveat: Cross-trial comparison is misleading because patient populations, baseline BMI, adjunctive lifestyle interventions, and trial duration differ. The numbers above are still the canonical reference figures clinicians and patients use to set expectations, but individual response varies widely.

Boxed warnings and DEA scheduling

Three categorical safety distinctions matter for the appetite-suppressant decision:

• Boxed warnings (FDA's strongest safety warning): All four GLP-1 RAs (Wegovy, Zepbound, Saxenda, Foundayo) carry the same thyroid C-cell tumor BBW based on rodent data. Saxenda's wording is categorical (“causes”) while the semaglutide/tirzepatide/orforglipron versions say “unknown whether [drug] causes thyroid C-cell tumors in humans.” Contrave carries a boxed warning for suicidality based on the bupropion antidepressant class. Qsymia, Xenical, and Phentermine have NO boxed warning.
• DEA scheduled-substance status: Phentermine (alone) is DEA Schedule IV — the lowest controlled-substance tier, indicating a recognized abuse potential. Qsymia contains phentermine + topiramate but is NOT itself DEA scheduled (phentermine is dose-titrated within the combination). Contrave, Xenical, and the GLP-1 RAs are NOT DEA controlled. Schedule IV status materially changes how phentermine can be prescribed online: the Ryan Haight Act of 2008 governs all internet-delivered controlled- substance prescriptions. See our How to Get Phentermine Online (FDA-Approved Telehealth Pathways) guide for the legitimate-pathway framework.
• REMS programs: Qsymia has a Risk Evaluation and Mitigation Strategy (REMS) program — only certified pharmacies can dispense it, due to topiramate's fetal toxicity risk. Contrave does not have a REMS. Phentermine does not have a REMS. The GLP-1 RAs do not have REMS but all carry the BBW.

Cost reality (2026)

Cash-pay landscape verified live July 2026:

• Foundayo (oral GLP-1): $149/mo at LillyDirect / Amazon Pharmacy — currently the cheapest brand-name FDA-approved weight-loss medication
• Wegovy (oral pill 1.5/4 mg): $149/mo at NovoCare through Aug 31, 2026
• Wegovy (standard pen): $299/mo at NovoCare self-pay
• Zepbound (vials): $299/$399/$449 by strength at LillyDirect Self Pay Journey Program
• Phentermine (generic): typically $9-30/mo at retail pharmacies — by far the cheapest option, but short-term use only
• Qsymia, Contrave, Xenical: brand-list prices of $200-500/month range; generic orlistat (alli OTC) is $30-60/month for the lower-dose 60 mg
• Insurance + manufacturer copay savings card: Wegovy, Zepbound, and Saxenda can be as little as $25/mo for commercially insured patients meeting eligibility

For the full channel-by-channel cash-pay guide, see GLP-1 cash-pay coupon & channel guide .

How to choose

• Want maximum weight loss + can do an injection + insurance covers it: Zepbound (tirzepatide).
• Want maximum weight loss + can do an injection + you have type 2 diabetes: Mounjaro (insurance covers for T2D); see our Mounjaro vs Zepbound comparison .
• Want a pill, not an injection: Foundayo (FDA-approved April 2026, oral GLP-1) is the strongest option. Qsymia is next strongest among non-GLP-1 oral options.
• Cannot tolerate GLP-1 GI side effects: Qsymia or Contrave are the next best non-GLP-1 prescription options. Xenical/alli has the most established long-term safety record but produces meaningful weight loss only with strict adherence to a low-fat diet (and the GI side effects are “oily stools” vs GLP-1 nausea — different trade-off).
• History of depression or suicidal ideation: Avoid Contrave (boxed warning for suicidality).
• Pregnancy potential + female of reproductive age: Avoid Qsymia (REMS for topiramate fetal toxicity); avoid Saxenda/Wegovy/Zepbound/Foundayo (GLP-1 class is contraindicated in pregnancy); orlistat is the most pregnancy-compatible option but should still be discussed with prescriber.
• Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2: All four GLP-1 RAs are contraindicated. Qsymia, Contrave, Xenical, or short-term Phentermine are the alternatives.
• Cheapest possible cash-pay: Generic phentermine (~$9-30/mo) for short-term use; Foundayo $149/mo or Wegovy oral pill $149/mo for longer-term weight management.
• Strongest published 4-year safety data: Orlistat (Xenical/alli) — XENDOS ran 4 years and showed 37% relative-risk reduction in T2DM progression alongside modest weight loss.

What we did NOT include — non-FDA-approved “appetite suppressants”

Many products marketed as “natural appetite suppressants” or “weight loss supplements” are dietary supplements, not FDA-approved drugs. These include glucomannan, 5-HTP, green tea extract, garcinia cambogia, hoodia, chromium picolinate, and various proprietary blends. The published evidence for sustained weight loss with these products is generally weak. The FDA regulates dietary supplements very differently from drugs — no premarket efficacy or safety review is required. We do not include them in this FDA-approved comparison.

We also did not include compounded GLP-1 products (compounded semaglutide, compounded tirzepatide). These are prepared by 503A pharmacies and are not FDA-approved products in the regulatory sense — they are pharmacy- prepared variants. The FDA's enforcement-discretion grace period for compounded semaglutide ended February 2025; for compounded tirzepatide it ended October 2024. See our compounded semaglutide directory and compounded tirzepatide directory for ranked options.

What are the best losing weight pills, slim pills, or skinny pills?

“Best losing weight pills,” “slim pills,” and “skinny pills” are colloquial search terms for the same FDA-approved drug class covered in this article. There is no separate category of “slim pills” or “skinny pills” that is medically distinct from the 8 FDA-approved appetite suppressants ranked at the top of this page.

The published-efficacy ranking is: Zepbound (tirzepatide, −20.9% at 72 weeks) > Wegovy (semaglutide, −14.9% at 68 weeks) > Foundayo (orforglipron, ~−12 to −15% at 72 weeks) > Qsymia (phentermine/topiramate, −9.8% at 56 weeks) > Saxenda (liraglutide, −5–8% at 56 weeks) > Contrave (naltrexone/bupropion, −5–6% at 56 weeks) > orlistat (−3–5% at 1 year) > phentermine alone (qualitative label-only). Anything marketed as a “skinny pill” that is NOT one of these eight is either an unregulated supplement (see grade C/D in our supplements evidence-grade article ) or a contaminated foreign-sourced product (see our Mexican diet pills evidence review ).